Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

PTC Therapeutics, Opus Bank, Pearson, and More: What Is Going on With These Falling Stocks?

Although the broader markets are just down by a fraction of a percent, shares of five companies, PTC Therapeutics, Inc. (NASDAQ:PTCT), W&T Offshore, Inc. (NYSE:WTI), Skypeople Fruit Juice Inc (NASDAQ:SPU), Pearson PLC (ADR) (NYSE:PSO), and Opus Bank (NASDAQ:OPB), are losing considerably more ground on Monday.

In this article, we examine what is going on with the five stocks and see how the investors from our database are positioned towards each company.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see the details here).

stocks, analysis, market, numbers, business, ticker, trade, money, price, investment, index, chart


PTC Therapeutics, Inc. (NASDAQ:PTCT) shares have slid by 35% after the company provided a disappointing regulatory update on its lead product/product candidate Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy. According to the update, the FDA denied PTC’s first appeal of the refuse to file letter issued by the agency on February 22, 2016 regarding PTC’s NDA for Translarna. According to the company, PTC intends to escalate its appeal to the next supervisory level of the FDA. In addition, PTC disclosed that the CHMP of the EMA issued a request for supplemental information, including a request categorized as a major objection. The renewal of PTC’s MAA in Europe generally requires PTC to adequately address the points raised in the major objection. The major objection relates to the efficacy and overall risk-benefit profile of Translarna. Of the 749 funds we track, 13 funds owned $22.28 million worth of PTC Therapeutics, Inc. (NASDAQ:PTCT)’s stock, which accounted for 9.20% of the float on June 30, versus 12 funds and $40.31 million, respectively, on March 31.

Follow Ptc Therapeutics Inc. (NASDAQ:PTCT)
Trade (NASDAQ:PTCT) Now!

W&T Offshore, Inc. (NYSE:WTI) is down by 6.4% after Barclays analyst Thomas Driscoll downgraded the stock to ‘Underweight’ from ‘Equal Weight’ and trimmed his price target to $1 per share from the previous $2. Driscoll downgraded the stock because he is somewhat concerned about the company’s leverage situation and the broader difficult off-shore drilling environment. The number of funds from our database with holdings in W&T Offshore, Inc. (NYSE:WTI) inched up by one quarter-over-quarter to six at the end of June.

Follow W&t Offshore Inc (NYSE:WTI)
Trade (NYSE:WTI) Now!

On the next page, we find out why traders are selling Skypeople Fruit Juice, Pearson PLC, and Opus Bank.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.